Pfizer (PFE) shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.
Pfizer said it expects 2024 revenue to range from $61 billion to $64 billion, with adjusted earnings per share (EPS) projected between $2.75 to $2.95. According to estimates compiled by Visible Alpha, analysts project $63.01 billion in revenue and adjusted earnings of $2.93 per share.
For 2025, Pfizer projects the same revenue range, while analysts see a slight bump to $63.24 billion. Pfizer expects its adjusted EPS will rise slightly to $2.80 to $3.00, while analysts project $2.89.
Pfizer was successful in its goals to cut $4 billion in costs by the end of 2024, the company said Tuesday, with an additional $500 million in savings expected to be realized over the next year. The drugmaker has returned to revenue growth in its two most recent quarters for the first time since sales of its COVID vaccine peaked.
"We also expect to continue improving our operating margins with focused financial discipline," Chief Executive Officer (CEO) Dr. Albert Bourla said.
Pfizer shares recently traded up 4.5% but are still down about 8% this year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。